Temporal changes in resistance mechanisms in colonizing Escherichia coli isolates with reduced susceptibility to fluoroquinolones

Diagnostic Microbiology and Infectious Disease

Volumn 76, Issue 4, 2013, Pages 491-496

  Han, Jennifer H ^a,b   Nachamkin, Irving ^b   Tolomeo, Pam ^b   Mao, Xiangqun ^b   Bilker, Warren B ^b   Lautenbach, Ebbing ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Escherichia coli; Fluoroquinolones; Resistance

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; GENTAMICIN; LEVOFLOXACIN; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIUM ISOLATE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DIARRHEA; ESCHERICHIA COLI; FECES ANALYSIS; FEMALE; FLUOROQUINOLONE RESISTANT ESCHERICHIA COLI; GASTROINTESTINAL INFECTION; GENE MUTATION; GYRA GENE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARC GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TIME; URINARY CATHETER;

ESCHERICHIA COLI; FLUOROQUINOLONES; RESISTANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FECES; FEMALE; FLUOROQUINOLONES; GASTROINTESTINAL TRACT; HOSPITALIZATION; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; TIME FACTORS;

EID: 84880714520     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.04.018     Document Type: Article

References (21)

1. Barton T.D., Fishman N.O., Weiner M.G., LaRosa L.A., Lautenbach E. High rate of coadministration of di- or tri-valent cation-containing compounds with oral fluoroquinolones: risk factors and potential implications. Infect Control Hosp Epidemiol 2005, 26:93-99.
2. Chang T.M., Lu P.L., Li H.H., Chang C.Y., Chen T.C., Chang L.L. Characterization of fluoroquinolone resistance mechanisms and their correlation with the degree of resistance to clinically used fluoroquinolones among Escherichia coli isolates. J Chemother 2007, 19:488-494.
3. Donskey C.J. Antibiotic regimens and intestinal colonization with antibiotic-resistant Gram-negative bacilli. Clin Infect Dis 2006, 43(Suppl 2):S62-S69.
4. Gales A.C., Gordon K.A., Wilke W.W., Pfaller M.A., Jones R.N. Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. Diagn Microbiol Infect Dis 2000, 36:61-64.
5. Goering R.V., Tenover F.C. Epidemiological interpretation of chromosomal macro-restriction fragment patterns analyzed by pulsed-field gel electrophoresis. J Clin Microbiol 1997, 35:2432-2433.
6. Jacoby G.A. Mechanisms of resistance to quinolones. Clin Infect Dis 2005, 41(Suppl 2):S120-S126.
7. Kern W.V., Oethinger M., Jellen-Ritter A.S., Levy S.B. Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 2000, 44:814-820.
8. Komp Lindgren P., Karlsson A., Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003, 47:3222-3232.
9. Lautenbach E., Strom B.L., Nachamkin I., et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004, 38:655-662.
10. Lautenbach E., Metlay J.P., Bilker W.B., Edelstein P.H., Fishman N.O. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005, 41:923-929.
11. Lautenbach E., Fishman N.O., Metlay J.P., et al. Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis 2006, 194:79-85.
12. Lautenbach E., Tolomeo P., Mao X., et al. Duration of outpatient fecal colonization due to Escherichia coli isolates with decreased susceptibility to fluoroquinolones: longitudinal study of patients recently discharged from the hospital. Antimicrob Agents Chemother 2006, 50:3939-3943.
13. Lautenbach E., Metlay J.P., Weiner M.G., et al. Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance. Infect Control Hosp Epidemiol 2009, 30:18-24.
14. Lee I., et al. Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med 2009, 169:379-383.
15. Li X.Z., Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs 2009, 69:1555-1623.
16. Moon D.C., Seol S.Y., Gurung M., et al. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates. Int J Antimicrob Agents 2010, 35:76-79.
17. Morgan-Linnell S.K., Becnel Boyd L., Steffen D., Zechiedrich L. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother 2009, 53:235-241.
18. Richard P., Delangle M.H., Raffi F., Espaze E., Richet H. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant Gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 2001, 32:162-166.
19. Singh R., Swick M.C., Ledesma K.R., et al. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother 2012, 56:1680-1685.
20. Wang H., Dzink-Fox J.L., Chen M., Levy S.B. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother 2001, 45:1515-1521.
21. White D.G., Goldman J.D., Demple B., Levy S.B. Role of the acrAB locus in organic solvent tolerance mediated by expression of marA, soxS, or robA in Escherichia coli. J Bacteriol 1997, 179:6122-6126.